gmp
gmp

Find Novel Oncology Drugs in Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IDE196,Crizotinib

            Therapeutic Area: Oncology Product Name: IDE196

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ideaya Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 24, 2020

            Details:

            The study will evaluate IDE196 and crizotinib combination therapy in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including metastatic uveal melanoma (MUM), skin melanoma, lung cancer and colorectal cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IDE196,Binimetinib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ideaya Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 18, 2020

            Details:

            IDEAYA and Pfizer will form a Joint Development Committee (JDC), and there will be joint decision making and data sharing of the clinical trial results between the parties.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ASO-Centyrin drug conjugates

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ionis Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 06, 2020

            Details:

            Ionis has exercised an option to obtain a license to an antisense oligonucleotide (ASO)-Centyrin drug conjugate. Ionis is using Aro’s CENTYRIN technology to enhance activity of ASOs via tissue-specific delivery for efficient inhibition of disease-causing RNAs and proteins.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nirogacestat,PF‐06863135

            Therapeutic Area: Oncology Product Name: PF-03084014

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 05, 2020

            Details:

            Pfizer will sponsor and conduct the Phase 1b/2 study to evaluate the safety, tolerability and preliminary efficacy of the nirogacestat and PF‐06863135 combo, and will assume all costs associated with the study, other than expenses related to the manufacturing of nirogacestat.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ZEN-3694,Nivolumab,Ipilimumab

            Therapeutic Area: Oncology Product Name: ZEN-3694

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Cancer Institute

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 05, 2020

            Details:

            First clinical Study to Combine ZEN-3694 with BMS’s immune checkpoint inhibitors nivolumab and ipilimumab for treatment of ovarian cancer .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: ARCH Venture Partners

            Deal Size: $77.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering September 29, 2020

            Details:

            Dewpoint Therapeutics works on organelles inside cells called biomolecular condensates, which it believes can be harnessed to treat diseases including cancer and rare genetic disorders. Condensates are membrane-less droplets that help cells perform vital functions.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Paxalisib

            Therapeutic Area: Oncology Product Name: GDC-0084

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Kazia Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 22, 2020

            Details:

            The collaboration aims at investigating the use of Kazia’s new drug, paxalisib (formerly GDC-0084), in primary central nervous system (CNS) lymphoma, a potential new indication for the drug. DFCI will initiate an open-label phase II clinical trial of paxalisib in PCNSL.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rintatolimod

            Therapeutic Area: Oncology Product Name: Ampligen

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Erasmus University Medical Center

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 22, 2020

            Details:

            Median survival was approximately two-fold higher, that is 200%, in the Ampligen arm as compared to the historical controls.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PBCAR269A,Nirogacestat

            Therapeutic Area: Oncology Product Name: PBCAR269A

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: SpringWorks Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 21, 2020

            Details:

            PBCAR269A, Precision’s allogeneic CAR-T cell therapy candidate targeting B-cell maturation antigen, will be evaluated in combination with nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in patients with relapsed or refractory multiple myeloma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CAR T cell therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Servier

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 17, 2020

            Details:

            Under the terms of the new development and commercial license agreement between Servier and Precision, companies have added two additional hematological cancer targets beyond CD19 and two solid tumor targets to its CAR T development and commercial license agreement.

            PharmaCompass